Dayvigo (Lemborexant) Cost in Vermont: Prices, Insurance, and Savings for 2026

What Dayvigo Actually Costs in Vermont

The sticker price and the price you pay are rarely the same number. Eisai, the manufacturer, lists Dayvigo at $320 for a 30-day supply. That figure applies to uninsured patients filling at retail without any discount. In practice, Vermont retail pharmacies charge an average cash-pay price of roughly $85 per month in 2026, a figure shaped by pharmacy benefit manager negotiations and regional competition among independents and chains.

Several factors push the real out-of-pocket cost lower still. The Eisai savings card, available to commercially insured patients, can reduce copays to $0 for qualifying fills. Patients on high-deductible plans or those between jobs may find GoodRx-style discount cards bring the price into the $75 to $100 range at pharmacies like Kinney Drugs, CVS, and local Vermont independents. Price varies by location. Burlington and Montpelier pharmacies tend to cluster near the $85 average, while rural pharmacies in the Northeast Kingdom may quote slightly higher.

For context, Dayvigo's efficacy supports these costs. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly improved sleep onset latency and sleep maintenance compared to placebo over 30 nights in adults aged 55 and older. The clinical benefit is not trivial. Patients on the 10 mg dose fell asleep approximately 12 minutes faster than placebo and spent less time awake after initially falling asleep.

Vermont Medicaid Coverage for Dayvigo

Vermont Medicaid does cover Dayvigo, but you will need prior authorization. The PA process requires documentation that the patient has tried and failed, or has a contraindication to, at least one first-line agent. In most cases, this means a trial of generic zolpidem, suvorexant, or trazodone (used off-label for insomnia) before Medicaid will approve lemborexant.

The Vermont Department of Health Access (DVHA) manages the preferred drug list. As of early 2026, Dayvigo sits on the non-preferred tier for insomnia agents, which triggers the PA requirement. Your prescriber submits the PA form to the pharmacy benefit manager. Typical turnaround is 24 to 72 hours.

"Prior authorization for newer insomnia agents like DORAs is standard across most state Medicaid programs," notes the American Academy of Family Physicians clinical guidance on insomnia management. "Documenting an adequate trial of a first-line generic, typically 4 to 6 weeks at a therapeutic dose, is usually sufficient."

Patients enrolled in Vermont Medicaid managed care plans (such as those administered through DVHA's contracted MCOs) should confirm coverage with their specific plan, since formulary placement can shift during the plan year. If the PA is denied, your prescriber can file an appeal, and Vermont law requires a response within 72 hours for standard appeals or 24 hours for expedited ones.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Vermont vary widely in how they handle Dayvigo. Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna all maintain formularies that may include lemborexant, but tier placement differs.

Most commercial plans place Dayvigo on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) level, resulting in copays that range from $35 to $75 per fill before any manufacturer assistance. Plans with step therapy protocols may require a generic sleep aid trial first. Some employer-sponsored plans have no step therapy requirement at all.

A few practical steps to check your coverage:

1. Call the member services number on your insurance card and ask for the pharmacy benefit formulary status of lemborexant (NDC for 5 mg and 10 mg tablets).
2. Ask whether prior authorization or step therapy applies.
3. Request a coverage determination letter if the plan excludes Dayvigo entirely.

Medicare Part D plans in Vermont generally do cover Dayvigo, though it often falls on a specialty or non-preferred brand tier. The FDA-approved prescribing information notes that lemborexant is indicated for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. That label indication supports medical necessity arguments for Part D coverage appeals.

How the Eisai Savings Card Works in Vermont

Eisai offers a manufacturer copay savings card for Dayvigo that can reduce out-of-pocket costs significantly for eligible patients. The card is available to patients with commercial insurance. It does not apply to government-funded programs (Medicaid, Medicare, TRICARE, VA benefits).

Here is how it works. You enroll online or receive a card from your prescriber's office. Present it at the pharmacy alongside your insurance card. The savings card covers the difference between your plan's copay and the promotional price, which Eisai has set at $0 for qualifying patients as of 2026. There is an annual maximum benefit (typically $3,600 per year, or $300 per monthly fill), but most patients with standard copays will not hit that cap.

Vermont does not have any state-specific restrictions on manufacturer copay assistance cards for commercially insured patients. Some states have begun regulating accumulator adjustment programs, where insurers refuse to count copay card dollars toward deductibles. Vermont has not enacted such legislation as of May 2026, so in most cases your Eisai card payments will count toward your annual out-of-pocket maximum.

One important caveat: if your insurer uses a copay accumulator or maximizer program, the savings card funds may not reduce your deductible. Ask your plan administrator directly whether copay assistance counts toward your deductible and out-of-pocket maximum.

Compounded Lemborexant in Vermont

Compounded lemborexant is available in Vermont through licensed 503A compounding pharmacies. Under federal law, 503A pharmacies may compound medications pursuant to a valid patient-specific prescription when a prescriber determines a clinical need, such as a dose not commercially available or an allergy to an inactive ingredient in the brand product.

The legality is straightforward. Vermont follows the federal framework established by the Drug Quality and Security Act (2013), which allows 503A compounding under state pharmacy board oversight. The Vermont Board of Pharmacy licenses compounding pharmacies and conducts inspections consistent with USP standards.

Compounded lemborexant pricing varies by pharmacy. Some 503A pharmacies advertise significantly lower prices than the brand product. Patients should verify that any compounding pharmacy they use holds a current Vermont pharmacy license and complies with USP <795> standards for non-sterile compounding.

A word of caution. Compounded formulations are not FDA-approved, do not undergo the same bioequivalence testing as manufactured tablets, and potency can vary between batches. The FDA has stated that compounded drugs "are not FDA-approved" and that patients should "be aware of the risks." For a Schedule IV controlled substance like lemborexant, ensuring consistent dosing matters. Discuss the trade-offs with your prescriber before switching from brand Dayvigo to a compounded version.

Telehealth Prescribing of Dayvigo in Vermont

Vermont permits telehealth prescribing of Dayvigo. The state updated its telehealth parity laws during the COVID-era legislative sessions and has maintained broad prescribing authority for licensed clinicians conducting video or audio visits. Lemborexant is a Schedule IV controlled substance under the DEA, and the DEA's post-pandemic telehealth rule allows initial prescribing of Schedule III through V substances via telehealth without an in-person visit, provided the prescriber holds a valid DEA registration and state license.

HealthRX and similar telehealth platforms can evaluate Vermont residents for insomnia and prescribe Dayvigo when clinically appropriate. The prescription is sent electronically to a Vermont pharmacy (EPCS, electronic prescribing of controlled substances, is required for Schedule II through V drugs in Vermont). You pick up at your local pharmacy or use a mail-order pharmacy licensed in Vermont.

Telehealth visits for insomnia evaluation typically run 15 to 30 minutes. Your clinician will assess sleep history, screen for obstructive sleep apnea and other sleep disorders, review current medications for interactions, and determine whether a DORA like lemborexant is appropriate versus other options such as suvorexant (Belsomra) or cognitive behavioral therapy for insomnia (CBT-I), which the American Academy of Sleep Medicine recommends as first-line treatment.

How Lemborexant Compares on Cost

Dayvigo is one of three FDA-approved dual orexin receptor antagonists. The others are suvorexant (Belsomra, Merck) and quviviq (daridorexant, Idorsia). In Vermont, the relative pricing looks like this:

Suvorexant lost patent exclusivity considerations are ongoing, but as of 2026, generic suvorexant is not yet widely available. Brand Belsomra lists at approximately $400 per month. Daridorexant (Quviviq) lists at roughly $350 per month. Against both, Dayvigo's $320 list and $85 average cash price position it as the least expensive branded DORA in Vermont.

Generic alternatives outside the DORA class are dramatically cheaper. Zolpidem (generic Ambien) runs $5 to $15 per month. Trazodone for insomnia costs $4 to $10. These older agents work through different mechanisms (GABA-A modulation for zolpidem, serotonin antagonism for trazodone) and carry different side-effect profiles, including next-day sedation, complex sleep behaviors, and dependency risk with Z-drugs.

The SUNRISE-1 data showed lemborexant produced clinically meaningful improvements without the rebound insomnia or withdrawal effects associated with benzodiazepine receptor agonists [1]. The SUNRISE-2 extension study confirmed efficacy over 12 months, a duration few older hypnotics have been studied for.

Tips to Lower Your Dayvigo Cost in Vermont

Start with the Eisai savings card if you carry commercial insurance. That single step eliminates most or all of your copay for each fill. If you are uninsured, ask your pharmacy to run a GoodRx or RxSaver coupon. These discount aggregators often bring the price below $90 at Vermont chains.

For Vermont Medicaid enrollees, work with your prescriber to complete the prior authorization. Have documentation ready: a record of at least one failed generic (dates, doses, and reason for discontinuation). A clean PA submission reduces the back-and-forth that delays access.

If cost remains a barrier, Eisai also offers a patient assistance program (PAP) for uninsured or underinsured patients. Eligibility is income-based, typically at or below 400% of the federal poverty level. Applications go through the prescriber's office.

Consider 90-day fills. Many Vermont pharmacies and mail-order services offer a per-unit discount for 90-day supplies, and insurance plans often charge two copays instead of three for a 90-day fill. That is a 33% copay reduction built into your plan's benefit design.

"For patients on fixed incomes, I always recommend checking both the manufacturer program and the plan's mail-order option before assuming a branded sleep medication is out of reach," says guidance from the Endocrine Society's cost-of-care principles.

Clinical Considerations Before Starting Dayvigo

Lemborexant works by blocking orexin receptors OX1R and OX2R, suppressing the wake-promoting signal rather than sedating the brain. This mechanism produces a different side-effect profile than older hypnotics. The most common adverse effects in trials were somnolence (reported in 10% of patients on 10 mg vs. 1% on placebo), headache, and sleep paralysis [1].

Prescribers should screen for narcolepsy before initiating a DORA. Because these drugs block the same orexin pathway that is deficient in narcolepsy, giving them to patients with undiagnosed narcolepsy could worsen cataplexy. The FDA label carries a warning about this risk.

Lemborexant is metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (clarithromycin, itraconazole, certain HIV protease inhibitors) is contraindicated. Moderate inhibitors like fluconazole or verapamil require dose adjustment to 5 mg. Vermont prescribers should run a drug interaction check, especially in older patients on multiple medications.

The starting dose is 5 mg taken immediately before bedtime with at least 7 hours of intended sleep remaining. If 5 mg is tolerated but insufficiently effective, the dose may be increased to 10 mg. Doses above 10 mg have not been studied and should not be prescribed.